“…In addition to beta‐testing including roughly 30 clinicians with 50 patients in three settings (de Vogel, van den Broek, & de Vries Robbé, ; Douglas & Belfrage, ; Kötter et al ., ), research areas that have been subjected to peer review to date include interrater reliability (IRR; de Vogel et al ., ; Douglas & Belfrage, ; Doyle et al ., ; Kötter et al ., ; Smith et al ., ), concurrent validity between HCR‐20 Versions 2 and 3 (Bjørkly, Eidhammer, & Selmer, ; de Vogel et al ., ; Douglas & Belfrage, ; Strub, Douglas, & Nicholls, ), predictive validity of risk factor and/or summary risk ratings (de Vogel et al ., ; Doyle et al ., ; Strub et al ., ), incremental validity of summary risk ratings and relevance ratings vis‐à‐vis presence ratings (Strub et al ., ), and the influence of relevance and presence ratings in terms of influencing summary risk ratings (Smith et al ., ).…”